Význam testu sensitivity leukemický buněk na inhibitory kináz in vitro při rozhodování o léčbě imatinibem a dasatinibem u nemocných s CML

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F61989592%3A15110%2F08%3A00007429" target="_blank" >RIV/61989592:15110/08:00007429 - isvavai.cz</a>

Výsledek na webu

—

DOI - Digital Object Identifier

—

Jazyk výsledku

angličtina

Název v původním jazyce

Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients

Popis výsledku v původním jazyce

Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optime

Název v anglickém jazyce

Usefulness of in vitro sensitivity testing of leukemic cells to kinase inhibitors for the management of treatment with imatinib and dasatinib in CML patients

Popis výsledku anglicky

Background. Second generation Abl tyrosine kinase inhibitors (TKIs), such as dasatinib (DAS) or nilotinib, are currently available for the treatment of patients with chronic myeloid leukemia (CML) resistant or intolerant to imatinib (IM) therapy. The efficacy of TKIs can be evaluated in vitro by degree of inhibition of phosphorylation of selected signaling molecules downstream Bcr-Abl after incubation of leukocytes with the drug. Aim. To evaluate functional assay that enables the clinicians to predict therapy responses and the degree of resistance/sensitivity of Bcr-Abl-positive leukemia patients to TKIs. Methods. Quantitative real time RT-PCR (Q-RT-PCR) was performed to monitor the level of BCR-ABL transcripts. BCR-ABL mutational status was assessed using sequencing of the RT-PCR products. The in vitro test of sensitivity to TKIs was based on detection of inhibition of phosphorylation of Crkl and Phospho-Src Family kinases (SFK, Tyr416). The pellet of leukocytes was washed with Optime

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FD - Onkologie a hematologie

OECD FORD obor

—

Projekt

—

Návaznosti

Z - Vyzkumny zamer (s odkazem do CEZ)

Rok uplatnění

2008

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Haematologica: the hematology journal

ISSN

0390-6078

e-ISSN

—

Svazek periodika

93

Číslo periodika v rámci svazku

S1

Stát vydavatele periodika

IT - Italská republika

Počet stran výsledku

1

Strana od-do

—

Kód UT WoS článku

—

EID výsledku v databázi Scopus

—